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biotechnology, and nanomedicine to aid in the diagnosis 
and treatment of a variety of debilitating diseases.
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Abbreviations
°C  Centigrade
0D  Zero dimensional
1D  One-dimensional
2D  Two-dimensional
3D  Three-dimensional
4T1  Murine breast tumor mice
A549  Human lung adenocarcinoma epithelial cell 
line
Au  Aurum, gold
CD105  Endoglin
Ce6  Chlorin e6
CGN  Thermo-sensitive nanogel
CNT  Carbon nanotube
CrGO  Chemically reduced GO
Cu  Copper
CVD  Chemical vapor deposition
Da  Dalton
DNA  Deoxyribonucleic acid
DOX  Doxorubicin
FA  Folic acid
FACS  Fluorescence-activated cell sorting
FDA  Food and drug administration
Fe3O4  Ferric oxide
FGO  Fibrin-coated GO
FMA  Fluorescein O-methacrylate
g  Gram
G  Graphene
Ga  Gallium
Abstract This review article aims to provide an over-
view of chemically modified graphene, and graphene oxide 
(GO), and their impact on toxicology when present in bio-
logical systems. Graphene is one of the most promising 
nanomaterials due to unique physicochemical properties 
including enhanced optical, thermal, and electrically con-
ductive behavior in addition to mechanical strength and 
high surface-to-volume ratio. Graphene-based nanomate-
rials have received much attention over the last 5 years in 
the biomedical field ranging from their use as polymeric 
conduits for nerve regeneration, carriers for targeted drug 
delivery and in the treatment of cancer via photo-thermal 
therapy. Both in vitro and in vivo biological studies of gra-
phene-based nanomaterials help understand their relative 
toxicity and biocompatibility when used for biomedical 
applications. Several studies investigating important mate-
rial properties such as surface charge, concentration, shape, 
size, structural defects, and chemical functional groups 
relate to their safety profile and influence cyto- and geno-
toxicology. In this review, we highlight the most recent 
studies of graphene-based nanomaterials and outline their 
unique properties, which determine their interactions under 
a range of environmental conditions. The advent of gra-
phene technology has led to many promising new oppor-
tunities for future applications in the field of electronics, 
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GAP-43  Growth-associated protein 43
Gel  Gelatin
Gelatin-GNS  Gelatin graphene nanosheets
GO  Graphene oxide
GOT  Graphene oxide/TiO2
HB  Hypocrellin B
HeLa  Henrietta Lacks cell
HepG2  Human hepatoma
HLF  Human lung fibroblast
hMSC  Human mesenchymal stem cells
HPPH  2-(1-Hexyloxyethyl)-2-devinyl 
pyropheophorbide-alpha
IONP  Iron oxide nanoparticles
iPSC  Induced pluripotent stem cell
iTRAQ  Isobaric tags used for relative and absolute 
quantification
K  Kelvin
KClO3  Potassium chlorate
Kg  Kilogram
LA  Lactobionic acid
LC3  Light chain 3
LC–MS/MS  Liquid chromatography–tandem mass 
spectrometry
LP  Linear polyethylenimine
m  Meter
MCF7  Michigan cancer foundation-7 breast can-
cer cell
MFG  Multi-functional graphene
mg  Milligram
MG-63  Osteoblast-like cell line
MHC  Major histocompatibility complex
MHRA  Medicines and healthcare products regula-
tory agency
mL  Milliliter
MR  Magnetic resonance
M-rGO  Microbially reduced graphene oxide
MTT  Methyl thiazolyl tetrazolium
MTX  Methotrexate
MWNT  Multi-wall carbon nanotube
MyoD  Myogenin
NGR  Nitrogen ion-implanted graphene
Ni  Nickel
NIH-3T3  National institute of health 3T3 mouse 
fibroblast cell
NIR  Near-infrared
NOTA  1,4,7-Triazacyclononane-1,4,7-triacetic 
acid
NSC  Neural stem cell
O-GNR  Oxidized graphene nanoribbons
PDT  Photodynamic thermal therapy
PEG  Polyethylene glycol
PEI  Polyethylenimine
PET  Positron emission tomography
PGE-DSPE  1,2-Distearoyl-sn-glycero- 
3-phosphoethanolamine-
N-[amino(polyethylene glycol)]
MCF7  Michigan cancer foundation-7 breast  
cancer cell
pH  Power of hydrogen
PLA  Polylactic acid
PMEF  Primary mouse embryonic fibroblast
PTT  Photo-thermal therapy
PVP  Polyvinylpyrrolidone
RBC  Red blood cell
rGO  Reduced graphene oxide
rGONP  Reduced graphene oxide nanoplatelet
RNA  Ribonucleic acid
SiC  Silicon carbide
SKBR3  Sloan–Kettering breast cancer cell
SWNT  Single-wall carbon nanotube
T  Troponin
TCP  Tissue culture polystyrene
Ti  Titanium
TiO2  Titanium dioxide
TPa  Tera pascal
TRC105  Human chimeric monoclonal antibody to 
CD105
U251  Human glioma cell
UCNP  Up-conversion nanoparticles
UK  United Kingdom
US  United States
W  Watt
μg  Microgram
Introduction
There is only a relatively small contribution regarding the 
safety profile and toxicology data in the literature on gra-
phene-based materials outlining their interactions in bio-
logical systems with cells and tissues. Over the last 5 years 
alone, over 424 publications and cited articles relate to gra-
phene toxicology, which has increased to 1,015 publication 
by 2009 to approximately 3,753 in 2013, whereby the vast 
majority focus on the physical and material properties of 
graphene and is a subject of intensive research (Liao et al. 
2011; Hu et al. 2011). The physicochemical interaction of 
graphene, and their use in biological systems, is perhaps 
one of the newest and fastest growth areas of carbon-based 
nanomaterials research. Much study in this area is inspired 
by the myriad of possibilities of many useful biomedi-
cal applications relating to their unique properties and to 
address healthcare concerns relating to nanotoxicology 
(Liu et al. 2008; Chang et al. 2011a). There has been an 
intensive focus over the last 10 years in the application of 
carbon-based nanomaterials such as charcoal, graphite, 
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fullerene, single-wall carbon nanotubes (SWCNTs), multi-
wall carbon nanotubes (MWCNTs), and graphene. This 
is due to the exploitation of their unique properties, such 
as enhanced electrical, thermal, mechanical, and optical 
properties, which provides a range of different application 
areas from advanced electronics and imaging to biomateri-
als and biological sensors for diagnostic use. However, a 
major concern, involving graphene-based materials, is that 
there is a limited knowledge relating to their environmental 
toxicity and biological safety profile. The UK government 
body, the Medicines and Healthcare Products Regulatory 
Agency (MHRA), and the US Food and Drug Adminis-
tration (FDA) are now reviewing all forms of graphene 
and functionalized graphene oxide (GO) due to their poor 
solubility, high agglomeration, long-term retention, and 
relatively long circulation time in the blood (Begum et al. 
2011). Extensive testing is now deemed essential for gra-
phene-based materials both for now and in the near future 
to assess their biological safety profile, which is depend-
ent upon different physicochemical factors relating to their 
surface chemistry, charge, size, shape, and relative concen-
tration. Yet still there are many unresolved issues, which 
remain and need to be clarified before their eventual use 
for healthcare applications can be fully realized. The bio-
compatibility and toxicity behavior of graphene-based 
material in biological systems gives rise to many important 
fundamental issues that require significant attention, and 
numerous studies are now needed to fill the knowledge gap 
before being considered as truly ‘safe’ for human use.
Graphene structure and related properties
Graphene is composed of single-carbon atoms forming a 
sheet of close-packed hexagonal array of SP2 hybridized 
bonds and can be considered as large aromatic molecule. 
As such, they have attracted a significant amount of atten-
tion in recent times, especially in various areas of biophys-
ics and biotechnological applications (Mao et al. 2013b). 
The two-dimensional, graphene flat sheets can be formed 
into different geometries, which can be wrapped into spher-
ical structures (0D fullerenes, C20, C40, C60), rolled into 1D 
structures as a single-sheet CNTs, or stacked into 3D-lay-
ered structures such as graphite (Fig. 1) (Geim and Novo-
selov 2007). This is due to their exceptional material prop-
erties giving rise to unique chemical, electrical and thermal 
conductivity (~5,000 Wm−1 K−1), mechanical, optical 
transmittance (~97.7 %), structural, and thermal behavior, 
and has shown great promise for many application areas 
relating to electronics, semiconductor fabrication, and 
the biomedical industry (Zhu et al. 2010; Compton and 
Nguyen 2010; Rao et al. 2009). Graphene has a number 
Fig. 1  Graphene is a 2D build-
ing material for allotropes of 
carbon nanomaterials. It can be 
wrapped up into 0D buckyball, 
rolled into a 1D nanotube, or 
stacked into 3D graphite (Geim 
and Novoselov 2007)
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of fascinating physical characteristics such as the highest 
surface area (~2,600 m2/g) (Li et al. 2008) and a relatively 
high Young’s modulus (<1 TPa) among all known materials 
(Lee et al. 2008), and capable of mass production through 
a number of chemical manufacturing and material process-
ing such as non-covalent and covalent surface modification 
using surfactants, and biofunctionalization to exploit their 
unique properties (Shao et al. 2010). Moreover, graphene 
consists of a layer of π-conjugated systems usually involv-
ing six-atom rings. This planar structure offers an excellent 
capability to interact with a variety of aromatic compounds 
through π–π stacking interactions in the manufacture of 
nanocomposite materials and in the immobilisation of bio-
molecules such as peptides, antibodies, and other therapeu-
tic agents (Boehm 1986; Wintterlin and Bocquet 2009; Van 
Bommel et al. 1975; Lu et al. 1999a, b; Novoselov et al. 
2004). Therefore, graphene has generated great interest in 
the field of nanomedicine and has been successfully applied 
in biosensing applications via targeted and selective deliv-
ery (Shao et al. 2010; Akhavan et al. 2012b), bioimaging, 
cell culture, cancer detection, gene delivery (Boehm 1986; 
Wintterlin and Bocquet 2009; Van Bommel et al. 1975; Lu 
et al. 1999a, b; Novoselov et al. 2004; Berger et al. 2004; 
Li et al. 2009; Stankovich et al. 2006), disease diagno-
sis (Mohanty and Berry 2008), anti-bacterial compounds 
(Akhavan and Ghaderi 2009, 2010, 2012; Hu et al. 2010; 
Ma et al. 2011; Akhavan et al. 2011), anti-viral materials 
(Akhavan et al. 2012c), photo-thermal therapy (Yang et al. 
2012b; Zhang et al. 2011a; Akhavan et al. 2012a), drug 
delivery (Sun et al. 2008; Liu et al. 2008, Li et al. 2011; 
Zhang et al. 2010a), and tissue engineering applications 
(Park et al. 2010; Agarwal et al. 2010; Heo et al. 2011). 
Therefore, all of their interesting material properties propel 
graphene from the research laboratory to real-life biologi-
cal and clinical applications and show great potential for 
further exploitation and use within the biomedical industry 
ready for clinical use.
Graphene preparation and manufacture
The preparation of graphene can be divided in two main 
categories: (1) bottom-up and (2) top-down fabrication 
techniques. Bottom-up fabrication is achieved using several 
methods to prepare high-quality graphene such as chemical 
vapor deposition (CVD). These methods produce highly 
crystalline graphene, but are not suitable for mass produc-
tion (Graphene et al. 2010; Kim et al. 2011). For example, 
CVD is a method which opens up scalable and transparent 
high-quality graphene in ultra-high vacuum (UHV) condi-
tions (10−4–10−6 pa) at high temperature (1,000 °C) using 
gasses such as methane –CH4 (g) as a carbon source as high-
lighted in Fig. 2. The CVD process revolves around a piece 
of copper (Cu) foil on silicon substrate, which is used as 
catalyst, which graphene is able to grow as a fibrous ‘mat’-
like material. At very high temperatures in an extreme 
clean, UHV chamber (or environment), carbon from CH4 
forms graphene on top of the Cu or nickel (Ni) foil (Fig. 2). 
Current methods are derived from chemical modification, 
and functionalized GO and reduced graphene oxide (rGO) 
within the top-down category are achieved through chemi-
cal exfoliation (Novoselov et al. 2012; Dreyer et al. 2010). 
Chemical exfoliation, described by Schafhaeutl, in the 
1940s is a method, which uses a wide range of chemicals 
such as acid or alkali metals (e.g., potassium), fluoride salts 
of various types, and transition metals (e.g., iron, nickel), to 
obtain GO (Dreyer et al. 2010). Nineteen years after Schaf-
haeutl described this method, British chemist, Broid, used 
a chemical exfoliation process to manufacture GO. This 
method can characterize the molecular weight of graphite 
by using acids (e.g., sulfuric and nitric), as well as oxi-
dants, such as potassium chlorate (KClO3). Further exfo-
liation with ultrasonication, thermal or energetic conditions 
help to oxidize stacked layers of hexagonally arranged 
carbon atoms that are bonded together with an inter-planar 
force to obtain graphene layers. The use of this method led 
Methane
CVD Graphene grown on substrate+
Hydrogen
Ni/Cu
Fig. 2  Bottom-up fabrication, by chemical vapor deposition (CVD)
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to the formation and production of single-layer-reduced 
GO (Dreyer et al. 2010). Top-down fabrication involves a 
chemical reduction based on Hummer’s method (Hummers 
and Offeman 1958), and chemical oxidation of graphite 
followed by ultrasonication is highlighted in Fig. 3.
Use of graphene in biomedical applications
Owing to graphene’s low level of toxicity, the lethal dose 
(LD50) of graphite has been reported as 2 g/per kilo 
(Sebastian 2012); the following sections outline some of 
the most promising application areas, use of graphene for 
enhanced imaging, diagnostics and therapeutic applica-
tions in nanomedicine, and their use as novel materials 
for improved medical devices via improvements in their 
mechanical properties, and photosensitivity has received 
considerable attention, along with their health and safety 
and regulatory concerns (Yang et al. 2010, 2011a, b).
Drug delivery applications
The treatment of cancer represents a global challenge to 
public health care and is a leading cause of over 7 million 
deaths worldwide annually (Wood 2013; Boyle and Levin 
2008). One significant and area of great importance in the 
treatment of cancer is the application of chemotherapy. This 
approach has proved successful in the treatment of various 
cancers, such as acute promyelocytic leukemia (Jing 2001; 
Chen et al. 1997), lung (Carney et al. 1983; Umezawa et al. 
1966; Kouranos et al. 2011), head and neck cancers. How-
ever, the lack of therapeutic efficacy confines such clini-
cal applications due to drug resistivity, low efficiency of 
cellular uptake, and high proportion of side effects, such 
as liver and kidney damage (Calvert et al. 1989; Kintzel 
and Dorrt 1995), hair loss (Jaracz et al. 2005; Narang and 
Varia 2011), nausea and cardiac toxicity (Chithrani et al. 
2009; Geiger et al. 2010; Voortman and Giaccone 2006). 
Therefore, novel materials with minimal side effects, low 
toxicity, and high efficiency of targeted drug delivery 
enhance the bioavailability for chemotherapy, which is 
an area of increasing research interest (Abou-jawde et al. 
2003; Manuscript 2009). Lung cancer is the primary cause 
of death for all known cancers worldwide (Deaths 2011; 
Jemal et al. 2011), and due to the size and distribution, 
cyto-reductive surgery is rarely a viable treatment option. 
Chemotherapy based on cytotoxic drugs kills cancer cells, 
which is the main popular approach for treatment of lung 
cancer. However, the lack of targeting specificity leads to 
severe side effects such as hemorrhage (Manuscript and 
Factors 2008). More effective localized delivery can lead 
to substantial improvements in curative and therapeutic 
modes of action not only for chemical-based treatments, 
but for MRI gene delivery including contrast enhancers and 
radiation sensitizers. In addition, the precise diagnosis and 
therapy are difficult in most cases for the limited options 
available (Shi et al. 2013a). Therefore, enormous endeavor 
in biomedical research has been dedicated to developing 
new approaches for early-stage detection, diagnosis, and 
therapy of cancer, which is now commonly referred to as 
‘theranostics’ (Mura and Couvreur 2012). Driven by an 
unmet clinical need, highly integrated drug delivery nano-
carriers rely for simultaneous imaging and therapy are cur-
rently being evaluated (Huang et al. 2012; Melancon et al. 
2011; Liang 2011; Jokerst and Gambhir 2011). Graphene 
and its derivatives, such as GO, reduced GO, and GO nano-
composites, are some of the more well-known examples 
(Feng and Liu 2011). Externally controlled non-invasive 
drugs with reliable remote sensing and repeatable ‘on’ 
and ‘off’ molecular switches to control drug release have 
recently been receiving attention (Thomas et al. 2010). 
This method consists of drug-releasing technology via an 
external stimulus to induce carrier responsive and material 
properties. The external stimulus is usually derived from 
polarized or infrared (IR) light (Yavuz et al. 2009; Sherlock 
et al. 2012; Lu et al. 2008), magnetic field strength (Hoare 
Fig. 3  Top-down fabrication, solution based on Hummer’s method using ultrasonication
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et al. 2009; Thomas et al. 2010), ultrasound (Hu and Zhou 
2014), and radio frequency-induced drug delivery (Santini 
et al. 1999; Grayson et al. 2003).
Photo-thermal therapy (PTT)
Photo-thermal therapy (PTT) converts light or opti-
cal energy to heat by absorption of a range of nanomate-
rial (e.g., silica-coated gold nanoparticles), leading to the 
thermal ablation resulting in the death of cancer cells. In 
recent years, PTT as a minimally invasive, controllable, 
and highly efficient treatment method has drawn wide-
spread attention in the treatment of cancer. A large number 
of research groups have developed various light-absorbing 
nanomaterials as PTT agents (Huang et al. 2006; Chen 
et al. 2007; Yavuz et al. 2009; Wu et al. 2010; Dong et al. 
2011; Tian et al. 2011; Cheng et al. 2011, 2012; Yang et al. 
2010, 2012b, c; Moon et al. 2009; Liu et al. 2011; Wang 
et al. 2011, 2012), all with absorbance values in the near-
infrared (NIR) region (560–760 nm), which is the region 
ideal for controlling interactions with biological tissues. 
Despite the great promise of PTT in cancer treatment using 
nanomaterials, the development of a new generation of 
PTT agents with enhanced NIR absorption and multiple 
functions to realize imaging-guided highly effective cancer 
therapy still merits further effort. Carbon-based nanomate-
rials, such as CNTs, carbon nanohorns, and graphene, are 
being extensively studied as potential PTT agents (Moon 
et al. 2009; Liu et al. 2011; Wang et al. 2011, 2012; Yang 
et al. 2010, 2012b). Besides inorganic materials, organic 
nanoparticles, such as polypyrrole and other light-absorb-
ing conductive polymers, have also shown potential in 
PTT cancer ablation in a few recent studies (Cheng et al. 
2012; Yang et al. 2012c; Chen et al. 2012c; Zha et al. 
2013). Nanoparticle-based NIR-PTT provides an encourag-
ing remedy and strategy for efficient tumor ablation with 
minimum injury to the surrounding tissues. Up-conversion 
of nanoparticles (UCNPs) is a further approach to PTT. As 
an example, UNCP, water-dispersible nanocrystals, which 
is fluorophores and magnetic nanoparticles, whereby fer-
ric oxide (Fe3O4) is reacted with polyethylenimine-modi-
fied GO (PEI-GO) acting as a nanocarrier attached to the 
nanocrystals to yield PEI-GO–nanocrystal (Yan et al. 
2013). PEI-GO–UCNP is able to load water-insoluble anti-
cancer drugs, such as doxorubicin (DOX), with a superior 
loading capacity of 100 wt%, through hydrophobic, π–π 
stacking interaction between PEI-GO–UCNP, and an aro-
matic drug highlighted in Fig. 4. Chemotherapy and PTT 
when used in combination have been proven to reduce 
drug resistance, and to be an effective strategy to improve 
the cancer therapy efficacy (Tang et al. 2010; Tang and 
Mcgoron 2009; Hauck et al. 2008; Lee et al. 2010). In con-
trast, undesired damage to normal tissues may be caused 
by non-specific, untargeted drug delivery and heat sup-
plied to the tumor area. Moreover, recent studies suggest 
that graphene possesses a higher photo-thermal sensitivity 
than CNTs, and is more effective in PTT in the treatment of 
cancer (Markovic et al. 2011; Yang et al. 2010, 2012a; Tian 
et al. 2011).
Nerve repair and regeneration
There is currently an unmet clinical need for biocom-
patible and conductive materials used for neurological 
Rare Earth (RE): Er, Tm, Y, Yb
NaYF4:  Er3+, Tm3+,Yb3+
NaYF4 (UCNP) 
Er3+, Tm3+,Yb3+
NH2
NaYF4 - NH2
GO GO-PEI
CO
OH
CO
OH
CO
OH
CO
OH
CO
OH
CO
OH
CO
OH
COOH
COOH PEI
UCNP-NH2
C
GO-PEI-UCNP
Fig. 4  Schematic diagram of the procedure for GO–PEI–UNCP: Numbers of core-shell structured UCNPs covalently grafted with GO through 
polyethylenimine for advanced imaging, drug delivery, and photo-thermal therapy
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applications, which are crucial in the development of next 
generation of chronic (long-term) implants used in the 
peripheral and central nervous system (CNS). Nanoparti-
cles incorporated into polymeric conduits, acting as fillers, 
such as, graphene, CNTs, and fullerene, can become one 
possible solution in the production of conducting materials, 
which are necessary for stimulating cell growth, and deliv-
ery of therapeutic agents. Identification of neural stem cell 
differentiation is an essential stage for the practical appli-
cation of stem cell technology in regenerative medicine. 
Cell differentiation and monitoring is incredibly important 
for the application of neural stem cells (NSCs) in the treat-
ment of neurodegenerative disease such as Alzheimer’s 
(Steindler and Okun 2012), Parkinson’s disease (Steindler 
and Okun 2012; Daadi et al. 2012; Xie et al. 2012), and 
also, traumatic spinal cord injury (Li et al. 2012; Donnelly 
et al. 2012). Many conventional tools have been used to 
detect the differentiation potential of NSCs, as well as to 
distinguish the undifferentiated NSCs from differentiated 
neuronal and glial cells (Danova-alt et al. 2012; Ganat et al. 
2012; Piao et al. 2012; Buján et al. 2005; Xu et al. 2012).
Risk assessments of graphene‑based nanomaterials
According to the elemental composition of carbon atoms 
arranged within the graphene layer or as discrete nanopar-
ticles, knowledge of influential factors such as their surface 
chemistry (energy, charge, and wettability), morphology, 
geometry and aggregation behavior and solubility will 
influence the particle distribution within the surrounding 
environment. Nanoparticles when present in physiologi-
cal fluids such as plasma or serum redistribute themselves 
throughout the host tissues and are transported to the liver, 
lungs, spleen, heart, kidney, and bone marrow due to their 
material and surface properties, and how they interact as a 
consequence of proteins that adsorb on to the surface can 
cause nanoparticle aggregation and cell uptake (Gajewicz 
et al. 2012). Figure 5 illustrates the toxicology overview 
on the principal components of graphene, the tests that 
are required, risk factors, and their eventual characteriza-
tion, highlighting the need for standardization for testing 
this class of material. Investigation via in vitro studies has 
shown that the indirect contact with nanomaterials with 
mammalian cells causes cytotoxic reactions, such as oxi-
dant release via reactive oxygen species (ROS) and stress 
followed by cytokine release and inflammation, which is 
primarily in response to ROS (Nel 2005; Nel et al. 2006; 
Oberdörster et al. 2005), cell damage and lipid peroxidation 
of cellular membranes (Nel et al. 2006; Oberdörster et al. 
2005; Panessa-Warren et al. 2006, 2008). Such events are 
known to cause changes in gene expression, which involve 
irregular signaling cues influencing cell fate resulting in 
further inflammation (Cui et al. 2005). The toxicity profile 
of graphene and GO nanoparticles remains elusive, since 
their characterization, bulk and chemical composition are 
very similar at the nanometer length scale. Figure 6 shows 
the potential distribution of graphene, highlighting the 
target organs and systems and distribution throughout the 
human body (Zhao and Liu 2012). A number of previous 
studies report that pristine graphene or GO without further 
surface modification causes severe pulmonary distress after 
inhalation causing excessive inflammation (Duch et al. 
2011). Intravenous (i.v.) injection of functionalized gra-
phene into mice is known to accumulate in the lung result-
ing in pulmonary edema and granuloma formation (Wang 
et al. 2010; Zhang et al. 2011a, b). Furthermore, surface-
functionalized graphene with improved hydrophilicity and 
better stability in the physiological environment appears 
to be far less toxic (Singh et al. 2012; Yang et al. 2011a, 
b). In Fig. 6, graphene can easily enter into the lungs via 
the respiratory system and later distribute themselves in the 
circulatory system via the blood and lymph fluid (Fig. 6). 
Further investigation into the distribution of graphene has 
found that the materials can penetrate into the tissues of the 
heart, spleen, kidney, bone marrow, and liver. The major 
risks to health care associated with the manufacture of car-
bon-based nanomaterials are to the eyes and the lungs, and 
can cause substantial irritation and inflammation (Kayat 
et al. 2011).
Exposure assessment of graphene
Due to the ever expanding applications of nanotechnol-
ogy, human and environmental exposures to graphene-
based nanomaterials are likely to increase both now and 
in the near future (Seabra et al. 2014). It is still not clear 
how to establish the precise mechanism or precise labo-
ratory-based test for determining the potential toxicity of 
nanoparticles. In the development of novel nanomaterials, 
considerable effort is needed to perform as broader risk 
characterization as possible (Worth 2010). Currently, one 
of the general market risk assessment methods is exposure 
methods to determine whether an exposed population and 
dependent exposures factors like frequency, magnitude, 
and duration have a cumulative effect. Other methods rely 
upon hazard assessments like identification and characteri-
zation of known hazards. Environmental factors also deter-
mine the exposure levels and distribution of the chemicals 
in the natural environment such as the levels present in the 
soil, sediment, water, and air, and any analytical measures 
as to the conversion or deterioration of chemicals, and the 
media containing the specific agents movement throughout 
the environment. The specific risk of the materials can be 
estimated, processed, and individualized within any given 
systems, while the hazard assessments will qualitatively 
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identify the nature of adverse effects and quantitatively 
define dose effects and dose–response relationships. All 
of the most recent reviews focus on the most important 
aspects of the risk assessment of graphene-based nanoma-
terials, which determine the extent to which the range of 
concentration of a given chemical released into the envi-
ronment (e.g., level of exposure) overlaps in time and space 
with those that are toxic (e.g., hazardous to health) in a 
range of selected organisms in a given populations within 
the ecosystem. Considering factors such as exposure and 
medical treatments and due to the different variables, it is 
required to be very precise to consider the best graphene 
based nanomaterials. Such variables are often complex and 
are complicated further by established ecosystems, and the 
numerous inter-relationships, and multivariant pathways in 
the distribution of chemicals and nanoparticles in the natu-
ral environment (Toxicology 1990).
Hazard assessment of carbon-based nanomaterials
Hazard assurance that a chemical or nanoparticle can show 
up in the tissue of the host and any other living organism 
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is usually dependent upon the frequency, concentration, 
and duration of exposure of the materials due to factors 
including the magnitude, extent, and duration to cause 
toxic side effects. Individual assessments and combinato-
rial hazard assessments are now required, and are in great 
demand to identify and characterize the causative agents. 
This is primary due to exposure (as described previously), 
as a result of environment toxicity or in vitro or in vivo 
medical treatments using graphene either as an implantable 
device or as drug delivery carrier. Animal experiments are 
performed according to policy guidelines standardized by 
the Organization for Economic Co-operation and Develop-
ment (OECD) in the UK, and are known to determine com-
mon toxic characteristics of a broad range of materials and 
chemicals. This includes eco-toxicity or animal and human 
toxicity.
Animal and human toxicity
Toxicology studies are now becoming more advanced in 
small- and large-scale animal studies in vivo and human cell 
lines in vitro. Direct hazard assessments and current method-
ology for studying nanomaterials help to reveal gaps in the 
knowledge and deficiency of current assessments. For exam-
ple, the lethal dose (LD50) of graphite, CNTs, and fullerenes 
reported as 2 g/Kg (Sebastian 2012), 2 mg/Kg (Ragot et al. 
2010), and 1.2 g/Kg (Da Ros et al. 2001), respectively, in 
animals. It is essential to employ traditional risk assessments 
and control of substances hazardous to health (COSHH) 
procedures when dealing with engineered nanoparticles, as 
information from toxicology studies is often deficient for 
broad risk assessments to be made with regard to nanoma-
terials based on carbon due to their vast heterogeneity. The 
most common cytotoxicity assays to evaluate toxicity of 
graphene-related materials are apoptosis assay’s such as 
caspase-3,7 assays to measure cell death, cell adhesion and 
morphology, cytokine detection, hemocompatibility, hemol-
ysis; lactate dehydrogenase (LDH) assay to assess mem-
brane integrity; methyl thiazolyl tetrazolium (MTT) assay 
as a measure of metabolic activity, platelet activation, ROS 
generation, and genotoxicity (Bitounis et al. 2013; Valla-
bani et al. 2011; Zhang et al. 2010b; Schinwald et al. 2012; 
Chang et al. 2011b; Akhavan et al. 2012d; Liao et al. 2011; 
Sasidharan et al. 2012; Seabra et al. 2014). Since there is a 
very close relationship between mutation and damage to 
DNA, genotoxicity assays are considered as an early and 
important indicator of toxicity, which may lead to cancer 
and tumor development (Agemy et al. 2010). The MTT is 
perhaps the most popular assay among the cell-based assays, 
and used for cytotoxicity and cell viability when character-
izing nanomaterials. In addition, this method using CNTs 
as the test substrate has been reported to be problematic as 
a consequence of using graphene-based materials (Bitounis 
et al. 2013; Liao et al. 2011; Seabra et al. 2014). Therefore, 
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the cell proliferation assay (WST-8) is a preferred method 
instead of MTT (Liao et al. 2011). Thus, the most appropri-
ate cytotoxic assays must be used to evaluate the toxicity 
of graphene-based materials to avoid false data. Graphene-
based nanomaterials’ in vivo studies are mostly based on 
the evaluation of tissue distribution (bioaccumulation) and 
excretion from the body. The most common animal model 
used to evaluate in vivo toxicity of graphene-based materi-
als is the Zebrafish model (Fako and Furgeson 2009). The 
route of administration should be considered as an important 
parameter that impacts the toxicity of nanomaterials (Yang 
et al. 2013a). Based on the recent literature, it is clear that 
due to the increase in the importance of graphene-based 
materials, meticulous and accurate in vitro and in vivo stud-
ies and accurate testing models of toxicity of the growing 
graphene family are required and are now in great demand.
Eco‑toxicity of graphene‑based nanomaterials
Above all other living creatures on the earth, continual evo-
lution brought intelligence to mankind. Therefore, it is nec-
essary that the study of eco-toxicological hazards and their 
assessments are of considerable importance. In toxicology, 
the focus is on human as a species, but in ecotoxicology the 
focus is broadened significantly, regarding the safety and 
well-being of millions of other common and rare species. 
So environment factors could put human needs at risk due 
to indirectly addressing the safety of harmful chemicals, 
which can degrade or even destroy ecosystem (Toxicol-
ogy 1990). The terrestrial environment is similar ecologi-
cally to aquatic environments, because living organisms are 
often intertwined and share a common food chain associ-
ated with their natural environment. Two of the well-known 
organized biological communities are the plant and animal 
kingdom. The plants are almost affected directly by the 
level of exposure and the presence of pollutants in the air 
and in rain fall. However, animals and sometimes humans 
can become contaminated with heavy metals by uptake 
toxic compounds through the food chain, e.g., mercury 
compounds. In the aquatic ecosystem, there is direct con-
tact between the pelagic fauna and flora with the chemicals 
suspended or dissolved in water. In contrast, the food chain 
is considered as indirect contamination or deemed much 
slower than direct contamination. Both ecosystems can be 
contaminated by direct exposure or ingestion of the parti-
cles. The quantities of chemical substances, which are car-
ried by different media, such as in the air, soil, or water, are 
often variable in nature. Furthermore, in different media the 
bioavailability and dynamics are very different. Eventually, 
such variability and different approaches applied for ter-
restrial and aquatic organisms raise substantial concerns in 
terms of accurately determining the levels of toxicity when 
comparing similar ecosystems.
Toxicity of functionalized graphene oxide 
and functionalized graphene
There are very few reports available on the toxicity of gra-
phene in vitro (Liu et al. 2009; Singh et al. 2011; Sasid-
haran et al. 2011) and in vivo (Chang et al. 2011a; Yang 
et al. 2011a, b) compared to carbon nanostructures, fuller-
enes (Service 2003), and CNTs (Nakamura and Isobe 2003; 
Lacerda et al. 2006). The main parameters affecting cyto-
toxicity of this class of nanomaterial including graphene 
(Wang et al. 2010), GO (Hu et al. 2010), CNTs (Chang 
et al. 2011a; Lam et al. 2006), gold and silver nanoparti-
cles (Lee et al. 2011) in vitro and in vivo are concentra-
tion, shape, size, surface charge, energy, and wettability. 
Also, in vitro studies could be divided in two discrete sec-
tions: (1) cytotoxicity and (2) genotoxicity. Extensive stud-
ies have been performed relating to in vitro cytotoxicity of 
GO over the last 5 years. However, the investigation of new 
areas of concern relating to genotoxicity of nanomaterials 
is an important research theme, as there is a close correla-
tion between DNA damage, mutation, and the formation of 
cancers (Agemy et al. 2010). There is insufficient research 
carried out on the genotoxicity of graphene-based materials 
at present and warrants much further investigation.
Toxicity of functionalized GO
GO is water-soluble nanomaterial and has been investi-
gated extensively as a material for industrial applications 
for electronics and use in biomedical engineering. This is 
due to the large vacancy of planar surface area for efficient 
filling of aromatic drug molecules through π–π stacking 
interactions, and carboxyl (–COOH), epoxy (–C–O–C–), 
and hydroxyl (–OH) functional groups. Moreover, limita-
tion of GO use in a variety of biomedical applications is 
due to the absence of stable dispersions. In the following 
sections, we review current nanotoxicity studies carried out 
with GO over the last 5 years. Moreover, Tables 1 and 2 
provide a thorough summary of all of the current studies, 
which address functionalized GO cytotoxicity from in vitro 
and in vivo studies.
Functionalized graphene oxide toxicity in vitro
GO cytotoxicity Initially, the influence of GO on the via-
bility of A549 (human lung adenocarcinoma epithelial cell 
line) cells based on current data has shown that at low con-
centrations, GO does not enter into the cells and shows no 
signs of cytotoxicity. However, GO is known to be cyto-
toxic and is dose-dependent and known to cause oxidative 
stress in A549 cells, and induce a loss in cell viability at 
high concentrations (Chang et al. 2011a). Cell viabil-
ity tests depict significant cell destruction by 1.0 μg/mL 
1997Arch Toxicol (2014) 88:1987–2012 
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of reduced graphene oxide nanoplatelets (rGONPs) with 
average dimensions (ALDs) of 11 ± 4 nm, while the rGO 
sheets with ALDs of 3.8 ± 0.4 μm could show a signifi-
cant cytotoxic effect only at high concentration of 100 μg/
mL after 1-h exposure. Although oxidative stress and cell 
wall membrane damage were determined as the main 
mechanism involved in the cytotoxicity of the rGO sheets, 
neither of them could completely describe the cell destruc-
tions induced by the rGONPs, especially at the concentra-
tions ≤1.0 μg/mL (Akhavan et al. 2012e). In other studies, 
microbially reduced graphene oxide (M-rGO) indicated the 
significant biocompatibility on primary mouse embryonic 
fibroblast (PMEF) at concentrations of 100 μg/ml (Guruna-
than et al. 2013b). Furthermore, graphene chitosan synthe-
sized by covalent linkage of carboxyl groups of GO with 
amine functionalized groups of chitosan was investigated. 
The negatively charged GO in chitosan scaffolds was an 
important physical and chemical factor, which enhanced 
cell scaffold interactions, as shown in Fig. 7 (Depan et al. 
2011). Polyethylenimines (PEIs) are polymeric transfec-
tion agents, which are highly branched like and contains 
primary, secondary, and tertiary amino (–NH2) groups, 
whereas linear PEIs contain all secondary amines. The pro-
duction of linear PEI-grafted GO (LP-GO) conjugates, and 
their efficacy to transfer nucleic acids into the mammalian 
cells is investigated (Tripathi et al. 2013). The LP-GOs 
interact with negatively charged nucleic acids and trans-
port them efficiently into cells, therefore, indicating that the 
conjugates have high transfection efficiency and have bet-
ter cell viability compared to LP (Tripathi et al. 2013). In 
other studies, cytotoxicity and genotoxicity data of GO to 
human lung fibroblast (HLF) cells have been assessed with 
the MTT assay, sub-G1 measurements, and comet assays 
(Wang et al. 2013a), and the results present concentration 
dependency. This study considered four different concentra-
tions, 0, 1, 50, and 100 μg, and indicated better response to 
the higher concentration range. The cell response has been 
studied to synthesize lactobionic acid–polyethylene glycol 
(LA–PEG)-functionalized graphene oxide (LA–PEG–GO), 
PEG-functionalized graphene oxide (PEG–GO), PEI-func-
tionalized graphene oxide (PEI–GO), and GO. The resulting 
cell was response revealed more positive to GO, PEI–GO, 
PEG–GO, and LA–PEG–GO, respectively. The genotoxic-
ity induced by GO was more severe than the cytotoxicity to 
HLF cells. The toxic effect can be explained by the oxida-
tive stress mediated by GO. In addition, the electric charge 
on the surface of GO is crucial having shown to decrease the 
toxicity of GO (Wang et al. 2013a). No toxicity was observed 
on endothelial cells (ECs) grown on PEI–GO–UNCP, and 
high potential of dead cancer cells on PEI–GO–UNCP was 
observed (Yan et al. 2013). In other studies, toxicity evalu-
ation of acid-functionalized (Wan et al. 2013) GO induced 
autophagosome accumulation and the conversion of light Ta
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chain 3 (LC3-I) to LC3-II (LC3 represents a mammalian 
homologue of the yeast autophagy-related gene ATG8). In 
addition, GO accumulation in macrophage lysosomes indi-
cates the instability of lysosome membranes and leads to 
autophagic degradation (Wan et al. 2013). An investigation 
showed that GO was capable of stimulating myogenic dif-
ferentiation and revealed myotube formation on GO (Ku 
and Park 2013). In this case, myogenic differentiation was 
significantly enhanced on GO base on the protein expres-
sion, formation, and expression of differentiation specific 
genes (MyoD, myogenin, Troponin T, and MHC). So the 
results indicated that the potential application for skeletal 
tissue engineering of GO is to stimulate myogenic differ-
entiation (Ku and Park 2013). A further study investigated 
how PTT influenced cytotoxicity when using polyvinylpyr-
rolidone (PVP) functionalized GO (Qin et al. 2013). Here, 
folic acid (FA), a target molecule to cancer cells, was conju-
gated to GO via covalent –NH2 bonds, obtaining FA–NGO–
PVP and then illustrating an ideal pH-responsive nanocar-
rier for delivery of an anticancer drug doxorubicin (DOX) 
with the loading ratio more than 100 % (Qin et al. 2013). 
In other studies, GO, titanium dioxide (TiO2) (GO/TiO2) 
hybrid (GOT) was studied by using Ti (OC4H9)4 and GO as 
reactants. The result presented no toxicity of GO in vitro as 
an electron sink in GOT efficiently increased the photody-
namic therapy (PDT) activity (Hu et al. 2012). Furthermore, 
in vitro studies of fibrin-coated GO (FGO) indicated that 
high levels of alkaline phosphatase and calcium ion release 
lead to confirmation of osteo-inductive nature of FGO 
(Deepachitra et al. 2013), and MTT assay data showed the 
biocompatibility of osteoblast-like cell line MG-63 on GO. 
Furthermore, GO nanosheets used to induce in situ gela-
tion of doxorubicin hydrochloride as an anti-tumor drug 
(Ma et al. 2012). Introduction of small amount of GO into 
aqueous solutions of doxorubicin hydrochloride caused the 
formation of thixotropic gel without any chemical additives 
(Ma et al. 2012). Cell growth confirmed that the materials 
remained cytocompatible with GO‑based materials.
Fig. 7  a–i Fluorescence micrographs illustrating the proliferation of pre-osteoblasts on pure CS and CS–GO scaffolds at similar locations (e.g., 
the center) after 7 and 28 days, respectively (Depan et al. 2011)
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Genotoxicity of graphene‑based nanomaterials Investiga-
tions using nanoparticles less than 50 nm in each dimension, 
and GO with a lateral dimension of 2 μm and 1.5 nm in 
thickness at different concentrations were dependent factors 
in inducing genotoxicity, and graphene was found to cause 
the most damage to DNA (Qiao et al. 2013). A further study 
depicted DNA damage using nanoparticles of silicon diox-
ide (SiO2), ZnO, TiO2, tin (Sn), and CNTs at concentration 
higher than (100 μg/mL). Graphene concentrations higher 
than 1 μg/mL induced DNA damage at a significantly lower 
concentrations (Seabra et al. 2014; Qiao et al. 2013). Also 
the size-dependent genotoxic effects of rGO nanoplatelets 
(rGONPs) on mesenchymal stem cells (hMSCs) are inves-
tigated (Akhavan et al. 2012e). The rGONPs showed geno-
toxic effects on hMSCs through DNA fragmentation and 
chromosomal aberrations even at very low concentration of 
0.1 mg/mL, highlighting concerns when using stem cells for 
applications for use in regenerative medicine.
Functionalized GO toxicity in vivo Functionalized GO tox-
icity and their distribution have been studied in mice using 
radiolabeling techniques (Zhang et al. 2011b). Results indi-
cate that GO has sufficient biocompatibility when studied 
in parallel with red blood cells (RBCs). In addition, GO 
mainly deposited in the lungs and surrounding tissue, and 
no pathological variation was illustrated when exposed to 
mice at 1 mg/kg body weight of GO for 14 days. But at a 
higher dosage, 10 mg/kg body weight, pulmonary edema, 
longtime retention, high accumulation, granuloma formation, 
inflammation, and cell infiltration was observed (Zhang et al. 
2011b). Amino group termination covalently attached to GO 
via a six-arm branched glycol (PEG; 10 kDa) chains were 
conjugated to NOTA (1,4,7-triazacyclononane-1,4,7-triacetic 
acid, for 66Ga-labeling) and TRC105 (an antibody that binds 
to CD105) (Hong et al. 2012), and study of histology vali-
dated the characterization of the GO conjugates. The in vivo 
characterizations were performed in murine breast tumor 
mice (4T1), and great stability in mouse serum was exhib-
ited in 66Ga-NOTA-GO and 66Ga-NOTA-GO-TRC105 con-
jugates. Quick accumulation of 66Ga-NOTA-GO-TRC105 in 
tumor uptake remained stable (Hong et al. 2012). In another 
study, GO functionalization by iron oxide nanoparticles 
(IONPs) and gold, forming a multi-functional magnetic and 
plasmonic GO-IONP-Au nanocomposite with strong super-
paramagnetism, significantly enhanced optical absorbance in 
the NIR region (Shi et al. 2013b). Enhanced photo-thermal 
cancer ablation effect using GO-IONP-Au-PEG is realized 
in comparison with PEGylated GO used in earlier studies, 
as demonstrated in in vivo animal experiments. Moreover, 
the IONP and Au compartments in the GO-IONP-Au-PEG 
nanocomposite could prove to be advantageous for mag-
netic resonance (MR) and X-ray dual-modal imaging (Shi 
et al. 2013b). Non-covalently functionalized nanographene 
oxide sheet (nano-GO) with pluronic block copolymer and 
positively charged photosensitizers via electrostatic interac-
tions have been previously reported (Sahu et al. 2013). These 
applications were combined with photodynamic thermal ther-
apy (PDT) and PTT for cancer. Cancer cells show increased 
uptake when compared to normal cells by the use of the nano-
GO, and it showed no toxicity to cells in the absence of NIR. 
High tumor accumulation was observed as a complex was 
injected intravenously into the tumor. Then, total ablation 
of tissue caused by NIR explosion via PDT and PTT (Sahu 
et al. 2013). In further studies, it was shown that doxorubicin 
loaded on to polyethylene glycol (PEG)ylated graphene 
oxide (GO–PEG–DOX) facilitates combined chemotherapy 
and PTT (Zhang et al. 2011a). The GO–PEG–DOX nanopar-
ticle ability to combine local, site-specific chemotherapy with 
external near-infrared-photo-thermal therapy (NIR-PTT) 
significantly improved the therapeutic efficacy of cancer 
treatment. In addition, the pathologic examination of main 
organs improved, as their toxicity study showed less toxicity 
results with GO–PEG–DOX compared to DOX (Zhang et al. 
2011a). Furthermore, injection of 80 mg/kg polyethylene 
glycol–grafted graphene oxide (PEG–GO) into mice intrave-
nously was investigated (Miao et al. 2013) and demonstrated 
the enhancement of cellular delivery compared to chlorin 
e6 (Ce6), as a natural molecule, and a promising photosen-
sitizer. Accumulation of Ce6/Dox/PEG–GO in tumor tis-
sues is shown in molecular imaging of mice, and substantial 
disruption of tumor nuclei was observed (Miao et al. 2013). 
Furthermore, photosensitizer molecule, 2-(1-hexyloxyethyl)-
2-devinyl pyropheophorbide-alpha (HPPH or Photochlor®) 
loaded onto PEG-functionalized graphene oxide (GO) via 
supramolecular π–π stacking investigated and obtained GO–
PEG–HPPH complex, shows high HPPH loading efficiency. 
The in vivo distribution and delivery were tracked by fluo-
rescence imaging as well as positron emission tomography 
(PET) after radiolabeling of HPPH with 64Cu. Compared with 
free HPPH, GO–PEG–HPPH offers dramatically improved 
photodynamic cancer cell killing efficacy due to the increased 
tumor delivery of HPPH (Rong et al. 2014). In vivo biodis-
tribution, and potential toxicity of as-made GO and a number 
of polyethylene glycol (PEG)-functionalized GO derivatives 
with different sizes and surface coatings, after oral and intra-
peritoneal administration at high doses are investigated (Yang 
et al. 2013a). Insignificant tissue uptake via oral administra-
tion on 125I-labeled PEGylated GO derivatives is observed, 
indicating the rather limited intestinal adsorption of those 
nanomaterials. In contrast, PEGyalted GO derivatives highly 
accumulated, but not as-made GO, in the reticuloendothe-
lial (RES) system including liver and spleen were observed 
post-injection (i.p.) and are highlighted in Fig. 8. Moreover, 
studies based on histological examination of organ slices and 
hematological analysis discovered that insignificant toxic-
ity to the treated animals, although GO and PEGylated GO 
2002 Arch Toxicol (2014) 88:1987–2012
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derivatives were retained in the mouse over a long period of 
time after post-injection (Yang et al. 2013a).
Toxicity of functionalized graphene
Among the graphene-based materials, graphene due to its 
super hydrophobicity is potentially more toxic than GO. 
However, this can be lessened by functionalizing graphene 
with polar chemical groups, which could aid the water sol-
ubility of graphene. In the following sections, we review 
the toxicity studies based on functionalized graphene (rep-
resented in Table 3) to present a summary of in vitro func-
tionalized graphene toxicity.
Functionalized graphene toxicity in vitro
Cytotoxicity of functionalized graphene In vitro toxic-
ity studies with graphene revealed better results compared 
to CNTs in inducing PTT to destroy the human glioma 
cells, U251 cell line (Markovic et al. 2011). This involved 
oxidative stress and mitochondrial membrane depolariza-
tion resulting in mixed apoptotic and necrotic cell death 
characterized by caspase activation/DNA fragmentation 
and cell membrane damage, respectively (Markovic et al. 
2011). In a further study, isobaric tags were used for rela-
tive and absolute quantification (iTRAQ)-coupled 2D liq-
uid chromatography–tandem mass spectrometry (LC–MS/
MS) approach to analyze the treated protein profile change 
in human hepatoma cells (HepG2) with graphene. The 
results showed less toxicity for moderate variation of pro-
tein levels for the cells treated with graphene (Yuan et al. 
2011). Mouse induced pluripotent stem cell (iPSCs) cul-
ture and spontaneous differentiation into ectodermal and 
mesodermal lineages supported by graphene was inves-
tigated (Chen et al. 2012b). Graphene surface illustrated 
similar cell proliferation and adhesion of iPSC compared 
Fig. 8  Biodistribution and clearance of NGS-PEG. a Time-depend-
ent biodistribution of 125I-NGS-PEG in female Bal b/c mice. b 
125I-NGS-PEG levels in the liver and spleen over time. c–e H&E 
stained liver slices from the untreated control mice (c) and NGS-
PEG injected mice at 3 days (d) and 20 days (e) p.i. Brown-black 
spots which could be clearly differentiated from the blue-stained cell 
nuclei were noted in the liver of mice 3 days after injection of gra-
phene. Much less black spots in the liver were observed 20 days later. 
f Statistic of black spot numbers in liver slices at various time post-
injection of NGS-PEG. Numbers of spots in full image fields under 
a ×20 objective were averaged over 5 images at each data point. g 
125I-NGS-PEG levels in urine and feces in the first week after injec-
tion. Mouse excretions were collected by metabolism cages. Error 
bars in the above data were based on standard deviations of 4–5 mice 
per group (Yang et al. 2011a, b)
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to glass substrates. Cytotoxicity effect-reduced graphene 
oxide nanoplatelets (rGONPs) on the human mesenchy-
mal stem cells (hMSCs) were investigated (Akhavan et al. 
2012e). The cell viability measurement indicated cell 
destructions at 1.0 μg/mL rGONPs; in contrast, the rGO 
sheets at concentration of 100 μg/mL illustrated a sig-
nificant cytotoxic effect (Akhavan et al. 2012e). A further 
investigation using a single-layer-reduced GO nanorib-
bons (rGONRs) produced via an oxidative unzipping of 
MWCNTs (Akhavan et al. 2013). The cell viability assay 
on hMSCs with concentration of 10 μg/mL rGONRs indi-
cated significant cytotoxicity effects, while the rGO sheets 
showed similar cytotoxicity at concentration of 100 μg/
mL. The results illustrate the penetration of rGONRs into 
the cells and DNA fragmentation, as well as, chromosomal 
aberrations at concentrations of 1.0 μg/mL (Akhavan et al. 
2013). The toxicity of graphene on macrophages and epi-
thelial cells was also investigated. The results indicate that 
the initial exposure to these materials is most prominent 
in respiratory system (Horváth et al. 2013). The interac-
tion of nitrogen ion-implanted graphene (NGR) has been 
evaluated with mouse fibroblast cells and human endothe-
lial cells, as well as in blood compatibility studies using 
rabbit blood (Guo et al. 2013). The results indicated the 
cell viability and proliferation improvement of cells cul-
tured on NGR compared with cells cultured on pristine 
graphene. Lower platelet adhesion, prolonged kinetic 
blood-clotting time, and hemolytic rate (below 5 %) pre-
sented for NGR showed thrombo-resistance than pristine 
graphene (Guo et al. 2013). The cytotoxicity of oxidized 
graphene nanoribbons (O-GNRs) water soluble with 
PEG–DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[amino(polyethylene glycol)]) was investigated 
(Mullick Chowdhury et al. 2013). The assays were con-
ducted on Sloan–Kettering breast cancer cells (SKBR3), 
Henrietta Lacks cells (HeLa) derived from cervical cancer 
tissue, Michigan cancer foundation-7 breast cancer cells 
(MCF7), and National Institute of Health 3T3 mouse fibro-
blast cells (NIH-3T3) (Mullick Chowdhury et al. 2013). 
All of the cells decrease in cell viability, as they repre-
sented a time-dependent (12–48 h) and dose-dependent 
(10–400 μg/mL) response. It was found that SKBR3 and 
MCF7 show a significantly lowered cytotoxicity compared 
to HeLa cells. The cells incubated at 10 μg/mL concentra-
tion were 100 % viable. As the concentration increased to 
400 μg/mL, the cell viability decreased to ~78 % of cells. 
On the other hand, significant dead cells were observed for 
HeLa cells even at concentration 10 μg/mL. The results 
indicated the heterogeneous cytotoxicity of O-GNR–PEG–
DSPEs, which possessed different cytotoxicity compared 
with chemically reduced graphene (Mullick Chowdhury 
et al. 2013). In a related study, composite poly (lactic acid) 
(PLA) and PLA film filled with graphene-based materi-Ta
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als investigated the biocompatibility. Graphene concentra-
tion of 10 μg/mL was used for mouse embryo fibroblasts 
incubated with both fillers. The results illustrate concen-
trations of graphene, and GO may perform decreased in 
toxicity biomedical applications (Pinto et al. 2013). Study 
of methotrexate (MTX) attached to the gelatin graphene 
nanosheets (gelatin-GNS) through strong π–π stacking 
interactions was conducted (An et al. 2013), and depicted 
great ability as a drug release, and high drug loading 
capacity of MTX. Based on the cytotoxicity results on 
A549 cell, the gelatin-GNS showed non-toxic at specific 
concentration while the MTX-gelatin-GNS depicted bio-
compatibility (An et al. 2013). Another study showed that 
protein-based facile method for fabrication of nanosized, 
reduced graphene oxide (nano-rGO) with high stability 
and low cytotoxicity was also investigated (Sheng et al. 
2013). Highly integrated constructed photo-acoustic/ultra-
sonic dual modality imaging and photo-thermal therapy 
platforms further demonstrated that the prepared nano-
rGO can be used as ready-to-use theranostic agents for 
both photo-acoustic imaging and photo-thermal therapy 
without further surface modification. Intravenous admin-
istration of nano-rGO in tumor bearing mice showed rapid 
and significant photo-acoustic signal enhancement in the 
tumor region, indicating its excellence for passive tar-
geting and photo-acoustic imaging. Meanwhile, using a 
continuous-wave near-infrared laser, cancer cells in vivo 
were efficiently ablated, due to the photo-thermal effect of 
nano-rGO (Sheng et al. 2013). Number of neurite on gra-
phene after cell seeding were enhanced during 7 days com-
pared with tissue culture polystyrene (TCP) substrates (Li 
et al. 2011). In addition, the growth-associated protein-43 
(GAP-43) was examined. Based on the results, GAP-43 
expression was significantly enhanced in graphene when 
compared to TCP. This could result in the boost of neur-
ite sprouting and outgrowth (Li et al. 2011). In brief, the 
presence of graphene indicated in vitro biocompatibility 
with different cell lines based on previous investigations. 
In contrast, there are not many sufficient studies on in 
vivo biocompatibility, which needs more investigations 
in this emerging field. Moreover, by functionalizing gra-
phene, as polymer filler, the surface topography changes, 
which causes an increase in roughness and surface energy 
to modify the wettability. The polar component of surface 
free energy increased with GO and decreased with gra-
phene added to the polymeric matrix.
Genotoxicity studies Hemin-graphene nanosheets 
(H-GNs) that are able to distinguish intact and damaged 
DNA and catalytic activity of hemin through graphene π–π 
interactions have successfully synthesized. Based on this, 
for detection of single-stranded DNA (ss-DNA) and dam-
age DNA induced by chemicals such as styrene oxide (SO), 
NaAsO2, and physical radiation, such as UV radiation, a 
free-label colorimetric method was developed. This method 
could be used to evaluate the new compounds’ genotoxicity, 
the maximum limit of pesticide residue, and food additives, 
due to its simplicity, sensitivity, speed, and cost-effective-
ness (Wei et al. 2013). Still, the molecular basis for in vivo 
graphene oxide (GO) toxicity is unclear. Caenorhabditis 
elegans has been used to investigate the microRNAs (miR-
NAs) control of GO toxicity. A total of 23 up-regulated and 
8 down-regulated miRNAs in GO-exposed nematodes were 
identified with the aid of SOLiD sequencing. The miRNA 
mutants were confirmed by the functions of identified miR-
NAs in regulating the GO toxicity on lifespan. Furthermore, 
the evidence to raise a hypothesis that GO may reduce lifes-
pan through influencing the functions of insulin/IGF signal-
ing, TOR signaling, and germline signaling pathways con-
trolled by miRNAs provided (Wu et al. 2014).
Functionalized graphene toxicity in vivo
There are no sufficient in vivo studies addressing the tox-
icity of graphene based on PubMed database. One of the 
current ongoing research themes is regarding the mag-
netization procedure and in situ reduction, which used to 
convert GO on to magnetic graphene. This was modified 
covalently to construct poly-acrylic acid (PAA) for link-
ing the fluorescein o-methacrylate (FMA) to yield multi-
functional graphene (MFG) with water dispersibility based 
on 2.5 mg/mL concentration (Gollavelli and Ling 2012). 
In vivo studies with zebra fish indicated no effect on the 
survival rate after MFG microinjection, nor any significant 
abnormalities. Meanwhile, in vivo studies on HeLa cells 
presented that MFG is a biocompatible imaging probe with 
concentrations in the range of 100 μg/mL (Gollavelli and 
Ling 2012). Graphene nanoparticle dispersions indicated 
the multifunctional agents for in vivo biomedical applica-
tions. Therefore, regulatory guidelines for pharmaceuti-
cals is followed, which recommend safety pharmacology 
assessment at least 10–100 times higher than the projected 
therapeutic dose and present comprehensive single dose 
response, expanded acute toxicology, toxico-kinetics, and 
cardiovascular pharmacology results for intravenously 
administered dextran-coated GO nanoplatelets (GNP-
Dex) formulations to rats at doses between 1 and 500 mg/
kg (Kanakia et al. 2014). The results presented that the 
maximum tolerable dose (MTD) of GNP-Dex is between 
50 mg/kg ≤ MTD < 125 mg/kg blood half-life <30 min, 
and majority of nanoparticles excreted within 24 h through 
feces. Histopathology changes were noted at ≥250 mg/kg 
in the heart, liver, lung, spleen, and kidney; no changes in 
the brain and no GNP-Dex-related effects in the cardio-
vascular parameters or hematological factors were found 
(blood, lipid, and metabolic panels) at doses <125 mg/kg 
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presented in Fig. 9. This result will open up new opportu-
nities for pivotal preclinical single and repeat dose safety 
studies following good laboratory practices (GLP) as man-
datory by regulatory agencies for investigational new drug 
(IND) applications (Kanakia et al. 2014).
Conclusion
Graphene-based nanomaterials have great potential for 
large number of future technologies ranging from bio-
technological and biomedical applications including, drug 
delivery, PTT, and cancer targeting and therapy. Graphene 
materials are known to vary widely in terms of their physi-
cal and chemical properties such as their dimensions and 
chemical functional groups. Moreover, they possess unique 
physical and chemical material properties such as opti-
cal, electrical and thermal conductivity, and high surface-
to-volume ratio. In addition, they can be easily linked to 
macromolecules through covalent or non-covalent attach-
ment. The types of graphene material and their chemi-
cal modifications to produce novel graphene compounds 
provide different levels of dispersibility and impurities 
within the nanomaterials. Based on the previous toxic-
ity investigations of graphene, graphene oxide and their 
derivatives all exhibit in vitro toxicity. However, it showed 
that cells are very sensitive to size, shape, solubility, and 
concentration of graphene nanomaterials. GO is consid-
ered more biocompatible than graphene due to its greater 
solubility/dispersibility, which results in less damage and 
toxicity in human cell types such as skin fibroblasts and red 
blood cells, and bacteria. Unfortunately, there are no cur-
rent or sufficient in vivo studies outlining their nanotoxic-
ity. The results indicate that upon initial exposure of the 
materials, the most prominent route into the human body 
lies within the respiratory system. However, they are less 
effective in liver, kidney, and spleen. Furthermore, all cells 
exhibit time and dosage dependency depending upon pro-
tein adsorption and reactions governed by aggregation. 
As this review represents only a few studies in relation to 
graphene-based materials, their toxicology profile remains 
at the very early stages of development for a range of bio-
medical applications. However, before such materials reach 
the clinic, their toxicology profile and safety efficacies are 
essential steps in their evolution. Such great potential will 
Fig. 9  Hematological results from blood pressure and echocardiogra-
phy measurements 10 min and 2 h post-injection of GNP-Dex (doses: 
1–500 mg/kg). a Blood pressure, b heart rate, c respiration rate, d 
atrioventricular mean blood velocity, e % ejection fraction (Kanakia 
et al. 2014)
◂
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offer a variety of new and powerful tools based on gra-
phene materials for use in the areas of advanced imaging, 
disease diagnosis, and targeted therapies for the treatment 
of a range of severely debilitating diseases.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
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